Anti-GPRC5D monoclonal antibody and its uses
Anti-GPRC5D monoclonal antibodies with high affinity address the need for effective cancer treatments by targeting and destroying GPRC5D-expressing cells, enhancing ADCC and endocytosis, and providing a therapeutic option for hematological cancers like multiple myeloma.
Patent Information
- Application Number
- JP2023540898
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-01-05
- Filing Date
- 2022-01-05
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-01-05
AI Technical Summary
Current treatments for cancers with high GPRC5D expression, such as multiple myeloma, are inadequate due to the lack of effective targeting and therapeutic agents.
Development of anti-GPRC5D monoclonal antibodies, including humanized derivatives, with high affinity for GPRC5D protein, which can target and destroy cancer cells through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and receptor-mediated endocytosis, and can be conjugated with cytotoxic drugs or used in bispecific formats to engage immune cells.
The antibodies effectively target and destroy GPRC5D-expressing cancer cells, inducing ADCC and endocytosis, and when conjugated with drugs, enhance tumor inhibition, demonstrating potential for clinical efficacy in treating hematological cancers like multiple myeloma.
Smart Images

Figure 0007595176000036 
Figure 0007595176000037 
Figure 0007595176000038
Abstract
Description
[Background technology]
[0001] G protein-coupled receptor family C group 5 member D (GPRC5D) is a member of the G protein-coupled receptor family. GPRC5D is a transmembrane protein. Overexpression of GPRC5D has been observed in patients with multiple myeloma. In particular, its high expression is significantly correlated with the poor outcome of disease and treatment.
[0002] Given its high specific expression on malignant cells, it has been proposed that antibodies specific for GPRC5D may be useful for treating malignant tumors, for example via bispecific T cell redirecting antibodies or by antibody-dependent cellular cytotoxicity (ADCC). Summary of the Invention [Means for solving the problem]
[0003] Discovered herein are anti-GPRC5D antibodies (including humanized derivatives thereof) that have high affinity for the human GPRC5D protein, which antibodies or fragments thereof can be used to treat cancer, particularly hematological cancers, because they can target cancer cells that express GPRC5D.
[0004] One embodiment of the present disclosure provides an antibody or antigen-binding fragment thereof having binding specificity for human G protein-coupled receptor family C group 5 member D (GPRC5D) protein, the antibody or fragment thereof comprising a heavy chain variable region (VH) comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, and a light chain variable region (VL) comprising complementarity determining regions CDRL1, CDRL2, and CDRL3. In some embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise: (a) the amino acid sequences of SEQ ID NOs: 29-34; (b) the amino acid sequences of SEQ ID NOs: 42-47; (c) the amino acid sequences of SEQ ID NOs: 54-59; or (d) the amino acid sequences of SEQ ID NOs: 68-73.
[0005] In some embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 29 to 34. In some embodiments, VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7 and 35 to 37, and VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 8 and 38 to 41. In some embodiments, VH comprises the amino acid sequence of SEQ ID NO: 35, and VL comprises the amino acid sequence of SEQ ID NO: 38.
[0006] In some embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 42 to 47. In some embodiments, VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9, and 48 to 50, and VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10, and 51 to 53. In some embodiments, VH comprises the amino acid sequence of SEQ ID NO: 48, and VL comprises the amino acid sequence of SEQ ID NO: 51.
[0007] In some embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 54 to 59. In some embodiments, VH comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 61 to 64, and VL comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 16, and 65 to 67. In some embodiments, VH comprises the amino acid sequence of SEQ ID NO: 61, and VL comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, VH comprises the amino acid sequence of SEQ ID NO: 63, and VL comprises the amino acid sequence of SEQ ID NO: 65.
[0008] In some embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 68 to 73. In some embodiments, VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and 74 to 79, and VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and 80 to 86. In some embodiments, VH comprises the amino acid sequence of SEQ ID NO: 76, and VL comprises the amino acid sequence of SEQ ID NO: 82. In some embodiments, VH comprises the amino acid sequence of SEQ ID NO: 77, and VL comprises the amino acid sequence of SEQ ID NO: 82.
[0009] In some embodiments, the antibody or fragment thereof is humanized, hi some embodiments, the antibody or fragment thereof is ADCC competent.
[0010] Additionally, the antibodies or fragments thereof provided, in some embodiments, further comprise a cytotoxic drug conjugated to the antibody or fragment thereof.
[0011] Also provided is a bispecific antibody comprising an antigen-binding fragment of the present disclosure and a second antigen-binding fragment having specificity for a second target protein. In some embodiments, the second target protein is selected from the group consisting of CD3, CD16, CD19, CD28, CD64, and 4-1BB. In some embodiments, the second target protein is CD3. In some embodiments, the second target protein is 4-1BB.
[0012] Also provided is a method of treating cancer in a patient in need of such treatment comprising administering to the patient an antibody or fragment thereof of the present disclosure.Also provided is a method of treating cancer in a patient in need of such treatment comprising (a) in vitro treatment of T cells, natural killer (NK) cells, or macrophages with an antibody or fragment thereof of the present disclosure, and (b) administering the treated cells to the patient.
[0013] In some embodiments, the cancer is a hematological cancer, such as a GPRC5D-expressing B-cell cancer (eg, multiple myeloma). [Brief description of the drawings]
[0014] [Figure 1] Binding of mouse antibodies harvested from hybridoma supernatants to GPRC5D expressed on CHO-K1 cells is shown. [Diagram 2] Binding of chimeric antibodies to GPRC5D expressed on CHO-K1 cells is shown. [Diagram 3] Antibody binding-induced endocytosis. [Figure 4] Showing that the antibody was ADCC competent. [Diagram 5] 1 shows the results of affinity testing of humanized antibodies derived from 6G10D9. [Figure 6] 1 shows the results of affinity testing of humanized antibodies derived from 58F9G10. [Figure 7] 1 shows the results of affinity testing of humanized antibodies derived from 34D3H1. [Figure 8] 1 shows the results of affinity testing of humanized antibodies derived from 37B9C4. [Figure 9] The binding of selected humanized antibodies to GPRC5D expressed on CHO-K1 cells is confirmed. [Figure 10] The binding of selected humanized antibodies to GPRC5D expressed on NCI-H929 cells is confirmed. [Figure 11] 1 shows the ADCC efficacy of the humanized antibodies tested. [Figure 12] 1 shows the internalization-inducing activity of the tested humanized antibodies. [Figure 13] 1 shows the cell killing activity of the antibody-drug conjugates tested. [Figure 14] The tumor-inhibitory activity of the tested antibodies is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] definition It should be appreciated that the term "a" or "an" entity refers to one or more of that entity; for example, "an antibody" is understood to refer to one or more antibodies. Thus, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.
[0016] The term "polypeptide" as used herein is intended to encompass the singular form "polypeptide" and the plural form "polypeptides" and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any chain of two or more amino acids and does not refer to a specific length of the product. Thus, peptide, dipeptide, tripeptide, oligopeptide, "protein", "amino acid chain", or any other term used to refer to one or more chains of two or more amino acids are included in the definition of "polypeptide", and the term "polypeptide" can be used instead or interchangeably for any of these terms. The term "polypeptide" is also intended to refer to products of post-expression modifications of the polypeptide, including, but not limited to, glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. Polypeptides may be derived from natural biological sources or produced by recombinant technology, but are not necessarily translated from a specified nucleic acid sequence. Polypeptides may be produced in any manner, including by chemical synthesis.
[0017] "Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing positions in each sequence that can be aligned for purposes of comparison. If a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous" sequence shares less than 40% identity, preferably less than 25% identity, with one of the sequences of the present disclosure.
[0018] A polynucleotide or polynucleotide region (or polypeptide or polypeptide region) has a particular percentage (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) of "sequence identity" to another sequence (meaning that, when aligned, a percentage of bases (or amino acids) are the same when comparing two sequences).
[0019] The term "equivalent nucleic acid or polynucleotide" refers to a nucleic acid having a nucleotide sequence with a particular degree of homology or sequence identity with the nucleotide sequence of a nucleic acid or its complement. A double-stranded nucleic acid homolog is intended to include a nucleic acid having a nucleotide sequence with a particular degree of homology with its complement. In one embodiment, a nucleic acid homolog can hybridize to a nucleic acid or its complement. Similarly, an "equivalent polypeptide" refers to a polypeptide having a particular degree of homology or sequence identity with the amino acid sequence of a reference polypeptide. In some embodiments, the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%. In some embodiments, an equivalent polypeptide or polynucleotide has one, two, three, four, or five additions, deletions, substitutions, and combinations thereof, compared to the reference polypeptide or polynucleotide. In some embodiments, an equivalent sequence retains the activity (e.g., epitope binding) or structure (e.g., salt bridges) of the reference sequence.
[0020] As used herein, an "antibody" or "antigen-binding polypeptide" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen. An antibody can be a whole antibody, and any antigen-binding fragment or single chain thereof. Thus, the term "antibody" includes any protein or peptide-containing molecule that contains at least a portion of an immunoglobulin molecule that has the biological activity of binding to an antigen. Examples of such include, but are not limited to, a heavy or light chain complementarity determining region (CDR) or a ligand-binding portion thereof, a heavy or light chain variable region, a heavy or light chain constant region, a framework (FR) region, or any portion thereof, or at least a portion of a binding protein.
[0021] As used herein, the term "antibody fragment" or "antigen-binding fragment" refers to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. The term "antibody fragment" includes aptamers, spiegelmers, and diabodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex.
[0022] A "single-chain variable fragment" or "scFv" is a fragment of an immunoglobulin heavy chain (V H ) and light chain (V L In some embodiments, the regions are linked with a short linker peptide of 10 to about 25 amino acids. The linker can be rich in glycine for flexibility and serine or threonine for solubility, and the V H The N-terminus of L or vice versa. This chimeric molecule retains the specificity of the original immunoglobulin despite the removal of the constant region and the introduction of a linker peptide. ScFv molecules are known in the art and are described, for example, in U.S. Pat. No. 5,892,019.
[0023] The term antibody encompasses a wide variety of classes of polypeptides that can be biochemically distinguished. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (γ, μ, α, δ, ε), with several subclasses within them (e.g., γ1-γ4). It is this property of the chain that determines the "class" of the antibody as IgG, IgM, IgA, IgG, or IgE, respectively. Immunoglobulin subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgG5, etc., are well characterized and are known to confer functional specialization. Modified versions of each of these classes and isotypes are readily discernible to the skilled artisan in light of the present disclosure, and are therefore within the scope of the present disclosure. All immunoglobulin classes are clearly within the scope of the present disclosure, and the following discussion will generally be directed to the IgG class of immunoglobulin molecules. For IgG, a standard immunoglobulin molecule contains two identical light polypeptide chains of molecular weight approximately 23,000 daltons and two identical heavy polypeptide chains of molecular weight 53,000-70,000. The four chains are typically joined by disulfide bonds in a "Y" configuration, in which the light chains surround the heavy chains starting at the opening of the "Y" and continuing through the variable region.
[0024] Antibodies, or antigen-binding polypeptides, variants, or derivatives thereof of the present disclosure include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, primatized, or chimeric antibodies, single chain antibodies, epitope-binding fragments such as Fab, Fab', and F(ab')2, Fd, Fv, single chain Fv (scFv), single chain antibodies, disulfide-linked Fv (sdFv), fragments comprising either the VK or VH domains, fragments produced by a Fab expression library, and anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies to the LIGHT antibodies disclosed herein). Immunoglobulin or antibody molecules of the present disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.
[0025] Light chains are classified as either kappa or lambda (K, λ). Each heavy chain class is associated with either a kappa or lambda light chain. Generally, when immunoglobulins are produced by either hybridomas, B cells, or genetically engineered host cells, the light and heavy chains are covalently linked to each other, and the "tail" portions of the two heavy chains are linked to each other by covalent disulfide bonds or non-covalent bonds. In the heavy chains, the amino acid sequences run from the N-terminus at the forked ends of the Y configuration to the C-terminus at the bottom of each chain.
[0026] Both light and heavy chains are divided into regions of structural and functional homology. The terms "constant" and "variable" are used in reference to function. In this regard, it will be appreciated that both the variable (VK) domain of the light chain portion and the variable (VH) domain of the heavy chain portion determine antigen recognition and specificity. Conversely, the constant domain of the light chain (CK) and the constant domain of the heavy chain (CH1, CH2, or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, etc. By convention, the numbering of the constant region domains increases as they become more distant from the antigen binding site or the amino terminus of the antibody. The N-terminal portion is the variable region and the C-terminal portion is the constant region; in fact, the CH3 domain and the CK domain comprise the carboxy terminus of the heavy and light chains, respectively.
[0027] As noted above, the variable region allows an antibody to selectively recognize and specifically bind to an epitope on an antigen. That is, the VK and VH domains, or a subset of complementarity determining regions (CDRs), of an antibody combine to form the variable region that defines a three-dimensional antigen-binding site. This tetrad of antibody structure forms an antigen-binding site at the end of each arm of a Y-shape. More specifically, the antigen-binding site is defined by three CDRs (i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) on each of the VH and VK chains. In some cases, for example, in certain immunoglobulin molecules derived from camelid species or engineered based on camelid immunoglobulins, the complete immunoglobulin molecule may consist of only heavy chains without light chains. See, e.g., Hamers-Casterman et al., Nature 363:446-448 (1993).
[0028] In naturally occurring antibodies, the six "complementarity determining regions" or "CDRs" present in each antigen-binding domain are short, non-contiguous sequences of amino acids that are specifically positioned to form the antigen-binding domain as the antibody assumes its three-dimensional configuration in an aqueous environment. The remaining amino acids in the antigen-binding domain, referred to as the "framework" regions, show less inter-molecular variability. The framework regions generally adopt a β-sheet conformation, and the CDRs form loops that hold together, and in some cases form part of, the β-sheet structure. Thus, the framework regions act to form a scaffold that provides for the correct orientation of the CDRs through inter-chain non-covalent interactions. The antigen-binding domain formed by the arrangement of the CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes non-covalent binding of the antibody to its cognate epitope. The amino acids which constitute the CDR and framework regions, respectively, have been precisely defined and can be readily identified by one of skill in the art for any given heavy or light chain variable region (see "Sequences of Proteins of Immunological Interest," Kabat, E., et al., USDepartment of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987)).
[0029] Where there are more than one definition for a term used and / or accepted in the art, the definition of the term used herein is intended to include all such meanings unless expressly stated to the contrary. A specific example is the use of the term "complementarity determining region" ("CDR") to describe the non-contiguous antigen binding sites found within the variable regions of both heavy and light chain polypeptides. This particular region is described by Kabat et al., USDept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983) and Chothia et al., J.MoI.Biol.196:901-917 (1987), which are incorporated herein by reference in their entireties. The CDR definitions according to Kabat and Chothia include overlapping or subsets of amino acid residues when compared to each other. Nevertheless, the use of either definition to refer to the CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues that encompass the CDRs defined by each of the above cited references are set forth in the following table for comparison. The exact residue numbers that encompass a particular CDR will vary depending on the sequence and size of the CDR. One of ordinary skill in the art can routinely determine which residues comprise a particular CDR given an antibody variable region amino acid sequence.
[0030] TIFF0007595176000001.tif47161
[0031] Kabat et al. also defined a numbering system for variable domain sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this "Kabat numbering" system to any variable domain sequence without relying on any experimental data other than the sequence itself. As used herein, "Kabat numbering" refers to the numbering system set forth by Kabat et al., U.S. Department of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).
[0032] In addition to the above table, the Kabat numbering system describes the CDR regions as follows: CDR-H1 begins at about amino acid 31 (i.e., about 9 residues after the first cysteine residue), includes about 5-7 amino acids, and ends at the next tryptophan residue. CDR-H2 begins at about the 15th residue after the end of CDR-H1, includes about 16-19 amino acids, and ends at the next arginine or lysine residue. CDR-H3 begins at about the 33rd amino acid residue after the end of CDR-H2, includes 3-25 amino acids, and ends with the sequence WGXG, where X is any amino acid. CDR-L1 begins at about residue 24 (i.e., after the cysteine residue), includes about 10-17 residues, and ends at the next tryptophan residue. CDR-L2 begins at about the 16th residue after the end of CDR-L1, and includes about 7 residues. CDR-L3 begins approximately 33 residues after the end of CDR-L2 (i.e., after the cysteine residue); includes approximately 7-11 residues and ends with the sequence F or WGXG, where X is any amino acid.
[0033] The antibodies disclosed herein can be of any animal origin, including avian and mammalian origin. Preferably, the antibodies are human, murine, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In another embodiment, the variable region can be of condricthoid origin (e.g., from sharks).
[0034] The term "heavy chain constant region" as used herein includes amino acid sequences derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain constant region comprises at least one of: a CH1 domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, an antigen-binding polypeptide used in the present disclosure may comprise a polypeptide chain comprising a CH1 domain; a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain comprising a CH1 domain and a CH3 domain; a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, and a CH3 domain, or a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, a CH2 domain, and a CH3 domain. In another embodiment, a polypeptide of the present disclosure comprises a polypeptide chain comprising a CH3 domain. Additionally, an antibody used in the present disclosure may lack at least a portion of a CH2 domain (e.g., all or a portion of a CH2 domain). As discussed above, it will be understood by those skilled in the art that the heavy chain constant region can be modified so that it differs in amino acid sequence from a naturally occurring immunoglobulin molecule.
[0035] The heavy chain constant regions of the antibodies disclosed herein may be derived from various immunoglobulin molecules. For example, the heavy chain constant region of the polypeptide may be derived from IgG l In another example, the heavy chain constant region may comprise a CH1 domain derived from an IgG molecule and a hinge region derived from an IgG3 molecule. l In another example, the heavy chain portion can include a hinge region derived in part from an IgG molecule.l The antibody may comprise a chimeric hinge derived from an IgG4 molecule and in part from an IgG4 molecule.
[0036] As used herein, the term "light chain constant region" includes amino acid sequences derived from an antibody light chain. Preferably, the light chain constant region includes at least one of the constant kappa domain or the constant lambda domain.
[0037] A "light-heavy chain pair" refers to a collection of light and heavy chains that can form dimers through disulfide bonds between the CL domain of the light chain and the CH1 domain of the heavy chain.
[0038] As mentioned above, the subunit structures and three-dimensional configurations of the constant regions of the various immunoglobulin classes are well known. As used herein, the term "VH domain" includes the amino-terminal variable domain of an immunoglobulin heavy chain, and the term "CH1 domain" includes the first (most amino-terminal) constant region domain of an immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is amino-terminal to the hinge region of the immunoglobulin heavy chain molecule.
[0039] The term "CH2 domain" as used herein includes, for example, the portion of a heavy chain molecule extending from about residue 244 to residue 360 of an antibody using conventional numbering schemes (residues 244-360, Kabat numbering system; and residues 231-340, EU numbering system; see Kabat et al., USDept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983)). The CH2 domain is unique in that it is not tightly paired with the other domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains in an intact native IgG molecule. It is also well documented that the CH3 domain extends from the CH2 domain to the C-terminus of the IgG molecule and comprises approximately 108 residues.
[0040] The term "hinge region" as used herein includes the portion of a heavy chain molecule that connects the CH1 domain to the CH2 domain. This hinge region contains approximately 25 residues and is flexible, allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be further divided into three distinct domains: the upper, middle, and lower hinge domains (Roux et al., J. Immunol 161:4083 (1998)).
[0041] The term "disulfide bond" as used herein includes a covalent bond formed between two sulfur atoms. The amino acid cysteine contains a thiol group that can form a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CK regions are linked by a disulfide bond, and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (positions 226 or 229, EU numbering system).
[0042] The term "chimeric antibody" as used herein shall be taken to mean any antibody in which the immunoreactive region or site is obtained or derived from a first species and the constant region (which may be intact, partial or modified in accordance with the present disclosure) is obtained from a second species. In certain embodiments, the target binding region or site is derived from a non-human source (e.g., mouse or primate) and the constant region is of human origin.
[0043] As used herein, "percent humanized" is calculated by determining the number of framework amino acid differences (i.e., non-CDR differences) between the humanized domain and the germline domain, subtracting that number from the total number of amino acids, dividing this by the total number of amino acids, and multiplying by 100.
[0044] "Specifically binds" or "has specificity for" generally means that an antibody binds to an epitope through its antigen-binding domain, and that the binding involves some complementarity between the antigen-binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an epitope if it binds to the epitope through its antigen-binding domain more readily than it would bind to a random, unrelated epitope. The term "specificity" is used herein to assess the relative affinity with which a particular antibody binds to a particular epitope. For example, antibody "A" may be considered more specific for a given epitope than antibody "B," or antibody "A" may be said to bind epitope "C" with greater specificity than to the related epitope "D."
[0045] The term "treat" or "treatment" as used herein refers to both therapeutic treatment and prophylactic or preventative measures, where the purpose is to prevent or slow down (alleviate) undesirable physiological changes or disorders, such as the progression of cancer. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, reduction in the extent of disease, stabilized (i.e., not worsening) disease state, delay or slowing of disease progression, remission or palliation of the pathology, and remission (either partial or total), of the disease state. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in whom the condition or disorder is to be prevented.
[0046] By "subject" or "individual" or "animal" or "patient" or "mammal" is meant any subject for which diagnosis, prognosis, or treatment is desired, particularly a mammalian subject. Mammalian subjects include humans, farm animals, and zoo, sport, or pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, dairy cows, and the like.
[0047] As used herein, phrases such as "a patient in need of treatment" or "a subject in need of treatment" include subjects, e.g., mammalian subjects, who would benefit from the administration of an antibody or composition of the disclosure, e.g., for use in detection, diagnostic procedures, and / or treatment.
[0048] Anti-GPRC5D antibody Using hybridoma technology, the attached experimental example shows that several mouse antibodies have been obtained. 14 of the mouse antibodies have been sequenced and humanized antibodies have been produced. These humanized antibodies exhibit strong GPRC5D binding activity and can induce receptor-mediated endocytosis. In vivo testing has shown that these antibodies have the activity of inducing ADCC and inhibiting tumor development.
[0049] Four of the murine antibodies, 34D3H1, 37B9C4, 58F9G10, and 6G10D9, underwent a humanization process. Some of the humanized antibodies, including 6-H3L3, 6-H4L3 (both derived from 6G10D9), 58-H1L1, 58-H3L1 (both derived from 58F9G10), 34-H1L1 (derived from 34D3H1), and 37-H1L1 (derived from 37B9C4), further showed promise for continued clinical development.
[0050] Thus, according to one embodiment of the disclosure, there is provided an antibody or antigen-binding fragment thereof having binding specificity to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein. The antibody or fragment thereof comprises a heavy chain variable region (VH) comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, and a light chain variable region (VL) comprising complementarity determining regions CDRL1, CDRL2, and CDRL3.
[0051] In some embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise (a) the amino acid sequences of SEQ ID NOs: 29 to 34; (b) the amino acid sequences of SEQ ID NOs: 42 to 47; (c) the amino acid sequences of SEQ ID NOs: 54 to 59 or SEQ ID NOs: 54, 60, and 56 to 59; or (d) the amino acid sequences of SEQ ID NOs: 68 to 73.
[0052] In one embodiment, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 29 to 34. Exemplary sequences for VH include SEQ ID NO: 7 and 35 to 37, or sequences having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NO: 7 and 35 to 37. Exemplary sequences for VL include SEQ ID NO: 8 and 38 to 41, or sequences having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NO: 8 and 38 to 41.
[0053] In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 35, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 35. In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 38, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 38.
[0054] Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that bind to the same epitope on FAPα as any one of these antibodies. Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that compete with any one of these antibodies for binding to FAPα, such as those having a VH comprising the amino acid sequence of SEQ ID NO:35 and a VL comprising the amino acid sequence of SEQ ID NO:38.
[0055] In one embodiment, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 42 to 47. Exemplary sequences for VH include SEQ ID NO: 9 and 48 to 50, or sequences having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NO: 9 and 48 to 50. Exemplary sequences for VL include SEQ ID NO: 10 and 51 to 53, or sequences having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NO: 10 and 51 to 53.
[0056] In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 48, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 48. In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 51, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 51.
[0057] Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that bind to the same epitope on FAPα as any one of these antibodies. Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that compete with any one of these antibodies for binding to FAPα, such as those having a VH comprising the amino acid sequence of SEQ ID NO:48 and a VL comprising the amino acid sequence of SEQ ID NO:51.
[0058] In one embodiment, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 54 to 59. Exemplary sequences for VH include SEQ ID NO: 61 to 64, or a sequence having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NO: 61 to 64. Exemplary sequences for VL include SEQ ID NO: 16 and 65 to 67, or a sequence having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NO: 16 and 65 to 67.
[0059] In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 61, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 61. In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 65, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 65.
[0060] Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that bind to the same epitope on FAPα as any one of these antibodies. Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that compete with any one of these antibodies for binding to FAPα, such as those having a VH comprising the amino acid sequence of SEQ ID NO:61 and a VL comprising the amino acid sequence of SEQ ID NO:65.
[0061] In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 63, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 63. In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 65, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 65.
[0062] Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that bind to the same epitope on FAPα as any one of these antibodies. Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that compete with any one of these antibodies for binding to FAPα, such as those having a VH comprising the amino acid sequence of SEQ ID NO:63 and a VL comprising the amino acid sequence of SEQ ID NO:65.
[0063] In one embodiment, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 54, 60, and 56 to 59, respectively. Exemplary sequences for VH include SEQ ID NO: 15, or a sequence having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NO: 15. Exemplary sequences for VL include SEQ ID NOs: 16 and 65 to 67, or a sequence having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NOs: 16 and 65 to 67.
[0064] In one embodiment, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NOs: 68 to 73. Exemplary sequences for VH include SEQ ID NOs: 1 and 74 to 79, or sequences having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NOs: 1 and 74 to 79. Exemplary sequences for VL include SEQ ID NOs: 2 and 80 to 86, or sequences having at least 85%, 90%, or 95% sequence identity to any of SEQ ID NOs: 2 and 80 to 86.
[0065] In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 76, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 76. In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 82, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 82.
[0066] Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that bind to the same epitope on FAPα as any one of these antibodies. Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that compete with any one of these antibodies for binding to FAPα, for example, those having a VH comprising the amino acid sequence of SEQ ID NO:76 and a VL comprising the amino acid sequence of SEQ ID NO:82.
[0067] In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 77, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 77. In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 82, or a sequence having at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 82.
[0068] Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that bind to the same epitope on FAPα as any one of these antibodies. Also provided, in some embodiments, are antibodies and antigen-binding fragments thereof that compete with any one of these antibodies for binding to FAPα, such as those having a VH comprising the amino acid sequence of SEQ ID NO:77 and a VL comprising the amino acid sequence of SEQ ID NO:82.
[0069] In some embodiments, the antibody or fragment thereof is ADCC competent. Suitable methods and materials for making antibodies ADCC competent are known in the art, for example, by using an appropriate Fc fragment or by reducing / removing fucosylation.
[0070] In some embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise: (a) the amino acid sequences of SEQ ID NOs: 29 to 34; (b) the amino acid sequences of SEQ ID NOs: 42 to 47; (c) the amino acid sequences of SEQ ID NOs: 54 to 59 or SEQ ID NOs: 54, 60, and 56 to 59; or (d) the amino acid sequences of SEQ ID NOs: 68 to 73, and each of the CDR sequences described contains one, two, or three conservative amino acid substitutions.
[0071] "Conservative amino acid substitution" refers to an amino acid residue that is replaced with an amino acid residue that has a similar side chain. A family of amino acid residues with similar side chains is defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, non-essential amino acid residues in immunoglobulin polypeptides are preferably replaced with another amino acid residue from the same side chain family. In another embodiment, a series of amino acids can be replaced with structurally similar stretches that differ in the order and / or composition of side chain family members.
[0072] Non-limiting examples of conservative amino acid substitutions are set forth in the table below, where a similarity score of 0 or greater indicates a conservative substitution between two amino acids.
[0073] TIFF0007595176000002.tif123161
[0074] TIFF0007595176000003.tif150161
[0075] It will also be understood by those of skill in the art that the antibodies disclosed herein can be modified to change their amino acid sequence from the naturally occurring binding polypeptide from which they are derived. For example, a polypeptide or amino acid sequence derived from a specified protein can be similar, e.g., have a particular percent identity to the starting sequence, e.g., be 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the starting sequence.
[0076] In some embodiments, the anti-CCR8 antibody is a modified mAb that comprises a modified heavy chain constant region, such as a defucosylated heavy chain, that binds to activating Fcγ receptors with higher affinity and mediates enhanced ADCC compared to unmodified mAbs. In some embodiments, the anti-CCR8 antibody comprises a heavy chain that is of the human IgG1 variant, including one or a combination of L234Y, L235Q, G236W, S239D / M, F243L, H268D, D270E, R292P, S298A, Y300L, V305I, K326D, A330L / M, I332E, K334A / E, P396L (all EU numberings), which enhance ADCC function.
[0077] In certain embodiments, the antibody comprises an amino acid sequence or one or more moieties not normally associated with antibodies. Exemplary modifications are described in more detail below. For example, the antibodies of the present disclosure may comprise a flexible linker sequence or may be modified to add a functional moiety (e.g., PEG, a drug, a toxin, or a label).
[0078] The antibodies, variants or derivatives of the present disclosure include derivatives that are modified by the covalent attachment of any type of molecule to the antibody, such that the covalent attachment does not prevent the antibody from binding to the epitope. For example, but not by way of limitation, the antibodies can be modified by, for example, glycosylation, acetylation, pegylation, phosphorylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, attachment to cellular ligands or other proteins, and the like. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like. In addition, the antibodies can contain one or more non-classical amino acids.
[0079] Antibody-drug conjugates GPRC5D is overexpressed on certain malignant blood cells, such as multiple myeloma cells. Thus, the antibodies and fragments of the present disclosure can be used to target malignant cells for inhibition, inactivation, destruction. In one example, the antibody or fragment is conjugated to an agent that aids in the inhibition, inactivation, or destruction of malignant cells. It has been shown herein that the antibody can induce GPRC5D-mediated endocytosis.
[0080] In some embodiments, the antibody or fragment may be conjugated to a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical, or PEG. In some embodiments, the conjugated agent may be a short interfering RNA (siRNA) or an intrinsic modulator, such as a stimulator of interferon genes (STING) agonist or a TLR7 / 8 agonist.
[0081] In one embodiment, the antibody or fragment of the present disclosure is covalently linked to a drug moiety. The drug moiety may be, or may be modified to contain, a group that reacts with a conjugation point on the antibody. For example, drug moieties can be attached by alkylation (e.g., at the epsilon-amino lysine or N-terminus of the antibody), reductive amination of oxidized carbohydrates, transesterification between hydroxyl and carboxyl groups, amidation at amino or carboxyl groups, and conjugation to thiols.
[0082] In some embodiments, the number of drug moieties conjugated per antibody molecule, p, ranges on average from 1 to 8; 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, p ranges on average from 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In other embodiments, p is on average 1, 2, 3, 4, 5, 6, 7, or 8. In some embodiments, p ranges on average from about 1 to about 20, from about 1 to about 10, from about 2 to about 10, from about 2 to about 9, from about 1 to about 8, from about 1 to about 7, from about 1 to about 6, from about 1 to about 5, from about 1 to about 4, from about 1 to about 3, or from about 1 to about 2. In some embodiments, p ranges from about 2 to about 8, from about 2 to about 7, from about 2 to about 6, from about 2 to about 5, from about 2 to about 4, or from about 2 to about 3.
[0083] For example, if chemical activation of the protein results in the formation of free thiol groups, the protein may be conjugated with a sulfhydryl-reactive agent. In one embodiment, the agent is substantially specific for free thiol groups. Examples of such agents include maleimides, haloacetamides (e.g., iodo, bromo, or chloro), haloesters (e.g., iodo, bromo, or chloro), halomethylketones (e.g., iodo, bromo, or chloro), benzyl halides (e.g., iodine, bromide, or chloride), vinylsulfones, and pyridylthios.
[0084] The drug can be linked to the antibody or fragment by a linker. Examples of suitable linkers include cleavable linkers and non-cleavable linkers. Cleavable linkers are typically susceptible to cleavage under intracellular conditions. Examples of suitable cleavable linkers include peptide linkers that can be cleaved by intracellular proteases, such as lysosomal or endosomal proteases. In exemplary embodiments, the linker can be a dipeptide linker, such as a valine-citrulline (val-cit), a phenylalanine-lysine (phe-lys) linker, or a maleimidocaproic-valine-citrulline-p-aminobenzyloxycarbonyl (mc-Val-Cit-PABA) linker. Another linker is sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate (smcc). Sulfo-smcc conjugation occurs through a maleimide group that reacts with sulfhydryls (thiols, -SH), while the Sulfo-NHS ester is reactive to primary amines (as found in lysines and protein or peptide N-termini). Yet another linker is maleimidocaproyl (mc). Other suitable linkers include linkers that are hydrolyzable at a particular pH or pH range, such as hydrazone linkers. Additional suitable cleavable linkers include disulfide linkers. Linkers such as mc linkers can be covalently attached to antibodies to the extent that the antibody must be degraded intracellularly to release the drug.
[0085] The linker may comprise a group for attachment to an antibody. For example, the linker may comprise an amino, hydroxyl, carboxyl, or sulfhydryl reactive group (e.g., maleimide, haloacetamide (e.g., iodo, bromo, or chloro), haloester (e.g., iodo, bromo, or chloro), halomethylketone (e.g., iodo, bromo, or chloro), benzyl halide (e.g., iodine, bromide, or chloride), vinylsulfone, and pyridylthio).
[0086] In some embodiments, the drug moiety is a cytotoxic or cytostatic agent, an immunosuppressant, a radioisotope, a toxin, or the like. The conjugate can be used to inhibit the proliferation of tumor or cancer cells, induce apoptosis in tumor or cancer cells, or treat cancer in a patient. The conjugate can be used in various settings accordingly for the treatment of animal cancer. The conjugate can be used to deliver drugs to tumor or cancer cells. Without being bound by theory, in some embodiments, the conjugate binds to or associates with cancer cells expressing GPRC5D, and the conjugate and / or drug can be taken up inside the tumor or cancer cells by receptor-mediated endocytosis.
[0087] Once inside the cell, one or more specific peptide sequences in the conjugate (e.g., in the linker) are hydrolytically cleaved by one or more tumor cell or cancer cell associated proteases, releasing the drug. The released drug is then free to migrate within the cell to induce cytotoxicity or cytostatic or other activity. In some embodiments, the drug is cleaved from the antibody outside the tumor or cancer cell, and the drug then enters the cell or acts at the cell surface.
[0088] Examples of drug moieties or payloads include DM1 (maytansine, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)- or N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine), mc-MMAD (6-maleimidocaproyl-monomethylauristatin-D or N-methyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1- [(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-(9Cl)-L-valinamide), mc-MMAF (maleimidocaproyl-monomethylauristatin F or N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine), and mc-Val-Cit-PABA-MMAE ( 6-Maleimidocaproyl-Val-Cit-(p-aminobenzyloxycarbonyl)-monomethylauristatin E or N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornityl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide). DM1 is a derivative of the tubulin inhibitor maytansine, while MMAD, MMAE, and MMAF are auristatin derivatives. In some embodiments, the drug moiety is selected from the group consisting of mc-MMAF and mc-Val-Cit-PABA-MMAE. In some embodiments, the drug moiety is a maytansinoid or an auristatin.
[0089] The antibody or fragment may be conjugated or fused to a detectable label, such as a therapeutic agent, which may include a radioactive label, an immunomodulator, a hormone, an enzyme, an oligonucleotide, a photoactive therapeutic or diagnostic agent, a cytotoxic agent (which may be a drug or a toxin), an ultrasound enhancing agent, a non-radioactive label, combinations thereof, and other such agents known in the art.
[0090] An antibody can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antigen-binding polypeptide is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds include luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt, and oxalate ester.
[0091] Antibodies may also be coupled to fluorescent metals, e.g. 152Antibodies can be detectably labeled with Eu, or others of the lanthanide series. The metals can be attached to the antibody using metal chelating groups such as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). Techniques for conjugating various moieties to antibodies are well known. For example, Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. (1985); Hellstrom et al., “Antibodies For Drug Delivery”, Controlled Drug Delivery (2nd Ed.), Robinson et al. al.,(eds.),Marcel Dekker,Inc.,pp.623-53(1987);Thorpe,“Antibody Carriers Of Cytotoxic Agents In Cancer Therapy:A Review”,Monoclonal Antibodies'84:Biological And Clinical Applications,Pinchera et al.(eds.),pp.475-506 (1985);“Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), Academic Press pp. 303-16 (1985), and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev. (52:119-58 (1982)).
[0092] Bifunctional Molecules and Combination Therapies GPRC5D is overexpressed on certain malignant blood cells, such as multiple myeloma cells. Thus, the antibodies and fragments of the present disclosure can be used to target malignant cells for inhibition of destruction, inactivation. In some embodiments, bifunctional or bispecific molecules / antibodies are provided that target both GPRC5D protein and immune cells.
[0093] In some embodiments, the immune cells are selected from the group consisting of T cells, B cells, monocytes, macrophages, neutrophils, dendritic cells, phagocytes, natural killer cells, eosinophils, basophils, and mast cells. Examples of molecules on immune cells that can be targeted include CD3, CD16, CD19, CD28, CD64, and 4-1BB (also known as CD137). Other examples include PD-1, CTLA-4, LAG-3 (also known as CD223), CD28, CD122, TIM3, OX-40 or OX40L, CD40 or CD40L, LIGHT, ICOS / ICOSL, GITR / GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM or BTLA (also known as CD272), killer cell immunoglobulin-like receptors (KIRs), and CD47. Specific examples of bispecifics include, but are not limited to, GPRC5D / CD3.
[0094] Various formats of bispecific antibodies are also provided. In some embodiments, the anti-PD-L1 fragment and the second fragment are each independently selected from a Fab fragment, a single chain variable fragment (scFv), or a single domain antibody. In some embodiments, the bispecific antibody further comprises an Fc fragment.
[0095] Polynucleotides encoding antibodies and methods for preparing antibodies The present disclosure also provides isolated polynucleotides or nucleic acid molecules encoding the antibodies, variants or derivatives thereof of the present disclosure. The polynucleotides of the present disclosure may encode the entire heavy and light chain variable regions of the antigen-binding polypeptide, variants or derivatives thereof on the same polynucleotide molecule or on separate polynucleotide molecules. In addition, the polynucleotides of the present disclosure may encode portions of the heavy and light chain variable regions of the antigen-binding polypeptide, variants or derivatives thereof on the same polynucleotide molecule or on separate polynucleotide molecules.
[0096] Methods for producing antibodies are well known in the art and described herein. In certain embodiments, both the variable and constant regions of the antigen-binding polypeptides of the present disclosure are fully human. Fully human antibodies can be produced using techniques described in the art and described herein. For example, fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigen challenge, but in which the endogenous locus has been disabled. Exemplary techniques that can be used to produce such antibodies are described in U.S. Patents: 6,150,584; 6,458,592; 6,420,140, which are incorporated by reference in their entireties.
[0097] Treatment The disclosed antibodies, variants or derivatives described herein may be used in certain treatment and diagnostic methods.
[0098] The present disclosure further relates to antibody-based therapeutic methods comprising administering the antibodies of the present disclosure to a patient, such as an animal, mammal, or human, for treating one or more of the disorders or conditions described herein. Therapeutic compounds of the present disclosure include, but are not limited to, the antibodies of the present disclosure (including variants and derivatives thereof as described herein) and nucleic acids or polynucleotides encoding the antibodies of the present disclosure (including variants and derivatives thereof as described herein).
[0099] The antibody of the present disclosure can also be used to treat or inhibit cancer.The GPRC5D provided above can be overexpressed in cancer cells, particularly in multiple myeloma.Inhibition of GPRC5D has been shown to be useful for treating cancer.
[0100] Thus, in some embodiments, provided is a method of treating cancer in a patient in need thereof. The method, in one embodiment, involves administering to the patient an effective amount of an antibody of the present disclosure. In some embodiments, at least one of the cancer cells in the patient overexpresses GPRC5D. In some embodiments, the antibody or fragment is ADCC competent. In some embodiments, the antibody or fragment further comprises a cytotoxic agent. In some embodiments, the antibody is bispecific, further targeting immune cells, such as cytotoxic T cells.
[0101] Also provided in the present disclosure is a cell therapy, such as a chimeric antigen receptor (CAR) T cell (or NK cell, macrophage) therapy. Appropriate cells can be used that are contacted with the anti-GPRC5D antibody of the present disclosure (or otherwise engineered to express the anti-GPRC5D antibody of the present disclosure). Such contact or engineering can then allow the cells to be introduced into a cancer patient in need of treatment. The cancer patient can have any type of cancer disclosed herein. The cells (e.g., T cells) can be, but are not limited to, tumor-infiltrating T lymphocytes, CD4+ T cells, CD8+ T cells, natural killer (NK) cells, macrophages, or combinations thereof.
[0102] In some embodiments, the cells are isolated from the cancer patient themselves. In some embodiments, the cells are provided by a donor or from a cell bank. If the cells are isolated from the cancer patient, unwanted immune responses can be minimized.
[0103] Non-limiting examples of cancer include blood cancers, such as multiple myeloma. Other examples include leukemias (acute leukemias (e.g., acute lymphocytic leukemia, acute myeloid leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)), chronic leukemias (e.g., chronic myelogenous (granulocytic) leukemia and chronic lymphocytic leukemia)), lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), and multiple myeloma.
[0104] The specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the specific antibody, variant or derivative thereof used, the patient's age, weight, health, sex, and diet, time of administration, excretion rate, drug combination, and the severity of the particular disease to be treated. The judgment of such factors by a medical caregiver is within the ordinary skill of the art. The amount will also depend on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity of the disease, and the desired effect. The amount used can be determined by pharmacological and pharmacokinetic principles well known in the art.
[0105] Methods of administration of antibodies include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. Antigen-binding polypeptides or compositions may be administered by any convenient route, such as, for example, infusion or bolus injection, absorption through epithelial or mucocutaneous (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other bioactive agents. Thus, pharmaceutical compositions containing antigen-binding polypeptides of the present disclosure may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (by powder, ointment, drops, or transdermal patch), bucally, or as an oral or nasal spray.
[0106] The term "parenterally" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
[0107] Administration can be systemic or local.In addition, it may be desired to introduce the antibody of the present disclosure into the central nervous system by any suitable route, including intraventricular injection and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, for example, an Ommaya reservoir.Pulmonary administration can also be used, for example, by using an inhaler or nebulizer and formulating with an aerosolizing agent.
[0108] It may be desirable to administer an antigen-binding polypeptide or composition of the disclosure locally to the area in need of treatment; this may be accomplished, for example and not by way of limitation, by local infusion during surgery, by topical application, for example in conjunction with a wound dressing after surgery, by injection, by catheter, by suppository, or by implant, said implant being of a porous, non-porous, or gelatinous material, including a membrane, such as a sialastic membrane, or fabric. Preferably, when administering a protein, including an antibody, of the disclosure, care should be taken to use a material to which the protein does not absorb.
[0109] The amount of the antibody of the present disclosure that is effective in treating, inhibiting, and preventing inflammatory, immune, or malignant diseases, disorders, or conditions can be determined by standard clinical techniques. In addition, in vitro assays can be optionally used to help identify optimal dosage ranges. The exact dose to be used in the formulation will also depend on the route of administration and the severity of the disease, disorder, or condition, and should be determined according to the judgment of the practitioner and each patient's circumstances. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0110] As a general proposition, the dosage of an antigen-binding polypeptide of the disclosure administered to a patient is typically 0.1 mg / kg to 100 mg / kg of patient's body weight, 0.1 mg / kg to 20 mg / kg of patient's body weight, or 1 mg / kg to 10 mg / kg of patient's body weight. Human antibodies generally have a longer half-life in the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower doses of human antibodies and less frequent administration are often possible. Additionally, the dosage and frequency of administration of the antibodies of the disclosure may be reduced by enhancing uptake (e.g., into the brain) and tissue penetration of the antibodies, for example, by modifications such as lipidation.
[0111] In additional embodiments, the compositions of the present disclosure are administered in combination with cytokines that may be administered with the compositions of the present disclosure, including, but not limited to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, anti-CD40, CD40L, and TNF-α.
[0112] In additional embodiments, the compositions of the present disclosure are administered in combination with other therapeutic or prophylactic regimens, such as radiation therapy.
[0113] Diagnostic methods Overexpression of GPRC5D has been observed in certain tumor samples, and patients with GPRC5D-overexpressing cells are likely to respond to treatment with the anti-GPRC5D antibodies of the present disclosure. Thus, the antibodies of the present disclosure can also be used for diagnostic and prognostic purposes.
[0114] Preferably, a sample containing cells can be obtained from a patient, which can be a cancer patient or a patient who wishes to be diagnosed. The cells can be tumor tissue or tumor block, blood sample, urine sample, or any sample cell from the patient. Optional pretreatment of the sample allows the sample to be incubated with the antibody of the present disclosure under conditions that allow the antibody to interact with the GPRC5D protein potentially present in the sample. Methods such as ELISA utilizing anti-GPRC5D antibodies can be used to detect the presence of GPRC5D protein in the sample.
[0115] The presence of GPRC5D protein in the sample (optionally by amount or concentration) can be used to diagnose cancer, as an indication that the patient is suitable for treatment with the antibody, or as an indication that the patient has responded (or has not) to cancer treatment. For predictive methods, detection can be performed once, twice or more times at a particular stage, upon initiation of cancer treatment, to indicate progress of treatment.
[0116] composition The present invention also provides pharmaceutical compositions. Such compositions include an effective amount of an antibody and an acceptable carrier. In some embodiments, the composition further includes a second anti-cancer agent (e.g., an immune checkpoint inhibitor).
[0117] In certain embodiments, the term "pharmaceutically acceptable" means approved by a regulatory agency of a federal or state government or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, and more particularly in humans. Moreover, a "pharmaceutically acceptable carrier" is typically a non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type.
[0118] The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like. The composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, such as acetates, citrates, or phosphates, if desired. Also contemplated are antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; and agents for adjusting tonicity such as sodium chloride or dextrose. The compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations, and the like. The compositions can be formulated as suppositories with conventional binders and carriers such as triglycerides. Oral formulations may include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutical carriers are described by EW Martin in Remington's Pharmaceutical Sciences, incorporated herein by reference. Such compositions contain a therapeutically effective amount of the antigen-binding polypeptide, preferably in purified form, together with a suitable amount of carrier so as to provide the patient with a suitable dosage form. The formulation should suit the mode of administration. The parent preparation can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
[0119] In one embodiment, the composition is formulated according to routine procedures as a pharmaceutical composition adapted for intravenous administration to humans. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. If necessary, the composition may also include a solubilizing agent and a local anesthetic, such as lignocaine, to ease pain at the injection site. Generally, the ingredients are supplied separately or combined together in a unit dosage form, for example as a lyophilized powder or water-free concentrate in a hermetically sealed container, such as an ampoule or sachet indicating the quantity of active agent. If the composition is to be administered by infusion, it can be dispensed by an infusion bottle containing sterile pharmaceutical grade water or saline. If the composition is to be administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
[0120] The compounds of the present disclosure can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions, such as those derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, and the like, and those formed with cations, such as those derived from sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, and the like. The present disclosure relates, for example, to the following: [1] 1. An antibody or antigen-binding fragment thereof having binding specificity for human G protein-coupled receptor family C group 5 member D (GPRC5D) protein, said antibody or fragment thereof comprising a heavy chain variable region (VH) comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, and a light chain variable region (VL) comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 are, respectively: (a) amino acid sequences of SEQ ID NOs: 42 to 47; (b) amino acid sequences of SEQ ID NOs: 29 to 34; (c) an amino acid sequence of SEQ ID NO: 54 to 59; or (d) Amino acid sequences of SEQ ID NOs: 68 to 73 An antibody or an antigen-binding fragment thereof comprising: [2] The antibody or antigen-binding fragment thereof according to [1] above, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 each comprise the amino acid sequences of SEQ ID NOs: 42 to 47. [3] The antibody or antigen-binding fragment thereof according to [2], wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 9 and 48 to 50, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 51 to 53. [4] The antibody or antigen-binding fragment thereof according to [2], wherein the VH comprises the amino acid sequence of SEQ ID NO: 48 and the VL comprises the amino acid sequence of SEQ ID NO: 51. [5] The antibody or antigen-binding fragment thereof according to [1] above, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequence of SEQ ID NO: 29 to 34. [6] The antibody or antigen-binding fragment thereof according to [5], wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 and 35 to 37, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 and 38 to 41. [7] The antibody or antigen-binding fragment thereof according to [5], wherein the VH comprises the amino acid sequence of SEQ ID NO: 35 and the VL comprises the amino acid sequence of SEQ ID NO: 38. [8] The antibody or antigen-binding fragment thereof according to [1], wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequences of SEQ ID NOs: 54 to 59. [9] The antibody or antigen-binding fragment thereof according to [8], wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 61 to 64, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16 and 65 to 67.
[10] The antibody or antigen-binding fragment thereof according to [8], wherein the VH comprises the amino acid sequence of SEQ ID NO: 61 and the VL comprises the amino acid sequence of SEQ ID NO: 65.
[11] The antibody or antigen-binding fragment thereof according to [8], wherein the VH comprises the amino acid sequence of SEQ ID NO: 63 and the VL comprises the amino acid sequence of SEQ ID NO: 65.
[12] The antibody or antigen-binding fragment thereof according to [1], wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the amino acid sequences of SEQ ID NOs: 68 to 73.
[13] The antibody or antigen-binding fragment thereof according to
[12] , wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and 74 to 79, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and 80 to 86.
[14] The antibody or antigen-binding fragment thereof according to
[12] , wherein the VH comprises the amino acid sequence of SEQ ID NO: 76 and the VL comprises the amino acid sequence of SEQ ID NO: 82.
[15] The antibody or antigen-binding fragment thereof according to
[12] , wherein the VH comprises the amino acid sequence of SEQ ID NO: 77 and the VL comprises the amino acid sequence of SEQ ID NO: 82.
[16] The antibody or fragment thereof according to any one of [1] to
[15] above, which is humanized.
[17] The antibody or fragment thereof according to any one of the above [1] to
[16] , which is ADCC competent.
[18] The antibody or fragment thereof according to any one of [1] to
[16] above, further comprising a cytotoxic drug conjugated to the antibody or fragment thereof.
[19] A bispecific antibody comprising the antigen-binding fragment according to any one of [1] to
[16] above, and a second antigen-binding fragment having specificity for a second target protein.
[20] The bispecific antibody according to
[19] , wherein the second target protein is selected from the group consisting of CD3, CD16, CD19, CD28, CD64, and 4-1BB.
[21] The bispecific antibody according to
[19] above, wherein the second target protein is CD3.
[22] A method for treating cancer in a patient in need of such treatment, comprising administering to the patient an antibody or a fragment thereof described in any one of [1] to
[21] above.
[23] A method for treating cancer in a patient in need of such treatment, comprising: (a) treating T cells, natural killer (NK) cells, or macrophages in vitro with the antibody or fragment thereof according to any one of [1] to
[21] above; and (b) administering the treated cells to the patient.
[24] The method according to
[23] , further comprising isolating the T cells, the NK cells, or the macrophages from an individual prior to step (a).
[25] The method according to
[24] , wherein the T cells, NK cells, or macrophages are isolated from the patient.
[26] The method according to any one of claims 23 to 25, wherein the T cells are tumor-infiltrating T lymphocytes, CD4+ T cells, CD8+ T cells, or a combination thereof.
[27] The method according to any one of the above
[22] to
[26] , wherein the cancer is a blood cancer.
[28] The method according to
[27] , wherein the blood cancer is a GPRC5D-expressing B-cell cancer.
[29] The method according to
[28] , wherein the GPRC5D-expressing B-cell cancer is multiple myeloma. EXAMPLES
[0121] Example 1: Generation of mouse monoclonal antibodies against human GPRC5D Human GPRC5D protein was used to immunize various strains of mice and hybridomas were generated accordingly. More than 20 hybridoma clones were collected for further analysis.
[0122] Antibodies harvested from the hybridoma supernatant were tested for binding to human GPRC5D protein expressed on CHO K1 cells. CHO-K1 cells stably expressing human GPRC5D were harvested from flasks. 1×10 6 100 μl of cells / ml were incubated with mouse antibodies in 3-fold serial dilutions for 30 minutes on ice. After washing twice with 200 μl of FACS buffer, cells were incubated with the second antibody for 30 minutes on ice. Cells were washed twice with 200 μl of FACS buffer, transferred to BD Falcon 5 ml tubes and analyzed by FACS. The results of the study showed that the mouse antibodies could bind to human GPRC5D with high EC50 (Figure 1). The results are shown in the table below. They all showed good binding activity.
[0123] TIFF0007595176000004.tif145161
[0124] Fourteen hybridomas were subcloned and the VH / VL sequences were determined (see Table 1).
[0125] [Table 1-1]
[0126] [Table 1-2]
[0127] [Table 1-3]
[0128] Example 2. Binding of chimeric antibodies to GPRC5D The mouse VH and VK genes were synthetically produced and then cloned into a vector containing the human gamma 1 and human kappa constant domains, respectively. Purified chimeric antibody was produced from transfected CHO cells.
[0129] CHO-K1 cells stably expressing human GPRC5D were harvested from a flask. 1 × 10 6 100 μl of cells / ml were incubated with primary chimeric antibodies in 3-fold serial dilutions starting from 300 nM to 0.001 nM for 30 min on ice. After washing twice with 200 μl of FACS buffer, cells were incubated with secondary antibodies for 30 min on ice. Cells were washed twice with 200 μl of FACS buffer, transferred to BD Falcon 5 ml tubes and analyzed by FACS. The results of the study showed that the chimeric antibodies could bind to human GPRC5D with high EC50 (Figure 2).
[0130] The results are shown in the table below.
[0131] TIFF0007595176000008.tif55161
[0132] Example 3. EC50 for internalization of chimeric GPRC5D antibodies on CHO-GPRC5D cells pHAb dyes are pH sensor dyes that have very low fluorescence at pH>7 and a dramatic increase in fluorescence as the pH of the solution becomes more acidic. pHAb dyes have an excitation maximum (Ex) at 532 nm and an emission maximum (Em) at 560 nm. pHAb dye-conjugated antibodies can be used to monitor receptor-mediated antibody internalization. The antibody-pHAb dye conjugate shows minimal fluorescence when bound to its receptor on the cell membrane. However, upon receptor-mediated internalization, the antibody-pHAb dye conjugates are transferred to endosomal and lysosomal vesicles where the pH is acidic and the pHAb dye fluoresces. This fluorescence can be detected using a variety of techniques, including cell imaging with appropriate filters, flow cytometry, and fluorescent plate-based readers.
[0133] Stably transfected human GPRC5D CHO cells were harvested with 0.05% trypsin / EDTA (Gibco, 25300-054) and plated at a density of 10K per 90 μl per well in 96-well black plates (Thermo Scientific #165305). Plates were incubated for 20-24 hours before treatment with pHAb-labeled antibody.
[0134] For internalization, pHAb-conjugated chimeric GPRC5D antibodies were added to the cells at different times and mixed gently on a plate mixer for 1-2 minutes, then incubated overnight to allow internalization (internalization can be detected in a few hours). Plates were read on a Tecan Infinity M1000 Pro fluorescent plate reader at Ex / Em: 532nm / 560nm. To achieve higher sensitivity, the medium was replaced by PBS before reading the plates.
[0135] The results normalized by DAR are shown in Figure 3. As shown in Figure 3, the chimeric antibodies tested have potent internalization activity.
[0136] Example 4. Antibody-dependent cellular cytotoxicity (ADCC) test The ADCC reporter bioassay uses a surrogate readout at an earlier point in the ADCC MOA pathway activation: activation of gene transcription via the NFAT (nuclear factor of activated T cells) pathway in effector cells. In addition, the ADCC reporter bioassay uses engineered Jurkat cells as effector cells that stably express the FcγRIIIa receptor, the V158 (high affinity) mutant, and an NFAT response element that drives expression of firefly luciferase. Antibody bioactivity in the ADCC MOA is quantified via luciferase generated as a result of NFAT pathway activation; luciferase activity in effector cells is quantified by a luminescence readout. The signal is high and the assay background is low.
[0137] Serial dilutions of GPRC5D chimeric monoclonal antibodies were incubated with engineered Jurkat effector cells (ADCC Bioassay Effector Cells) with or without ADCC bioassay target cells (GPRC5D) for 6 hours of induction at 37°C. Luciferase activity was quantified using Bio-Glo™ reagent (Figure 4). All tested antibodies showed strong ability to induce ADCC.
[0138] Example 5. Humanization of Mouse mAb Mouse antibody variable region genes were used to generate humanized mAbs. In the first step of this process, the VH and VL amino acid sequences of the mAb were compared against available databases of human Ig gene sequences to find the best matching entire human germline Ig gene sequence.
[0139] The amino acid sequences of the humanized antibodies are set forth below.
[0140] ヒトArrangement A.34D3H1
[0141]
Table 2A
[0142]
Table 2B
[0143]
Table 2C
[0144]
Table 2D
[0145]
Table 2E
[0146] B.37B9C4
[0147]
Table 3A
[0148]
Table 3B
[0149]
Table 3C
[0150]
Table 3D
[0151]
Table 3E
[0152] C.58F9G10
[0153]
Table 4A
[0154]
Table 4B
[0155]
Table 4C
[0156]
Table 4D
[0157]
Table 4E
[0158] D.6G10D9
[0159]
Table 5A
[0160]
Table 5B
[0161]
Table 5C
[0162]
Table 5D
[0163] [Table 5E]
[0164] Example 6. Testing of humanized antibodies This example tested some of the humanized antibodies for their ability to bind to GPRC5D expressed on CHO-K1 cells.
[0165] Of those tested, humanized antibodies derived from 6G10D9, 6-H2L1, and 6-H3L3 outperformed the others (Figure 5, Table 6).
[0166] [Table 6]
[0167] As shown in FIG. 6 and Table 7, all humanized versions of 58F9G10 appeared to perform well.
[0168] [Table 7]
[0169] Similarly, as shown in FIG. 7 and Table 8, all humanized versions of 34D3H1 appeared to perform as well as the chimeric antibody.
[0170] [Table 8]
[0171] Also, as shown in FIG. 8 and Table 9, all humanized versions of 37B9C4 appeared to perform as well as their chimeric counterparts.
[0172] [Table 9]
[0173] Based on the above data, humanized antibodies 6-H3L3, 6-H4L3, 58-H1L1, 58-H3L1, 34-H1L1, and 37-H1L1 were selected for further validation studies.
[0174] Example 7. Validation testing of selected humanized antibodies In this example, some of the humanized antibodies (6-H3L3, 6-H4L3, 58-H1L1, 58-H3L1, 34-H1L1, and 37-H1L1) were tested for their ability to bind to human GPRC5D protein expressed on CHO-K1 cells and NCI-H929 cells.
[0175] The binding data to CHO-K1 is plotted in FIG. 9 and summarized in Table 10 below.
[0176] [Table 10]
[0177] [Table 11]
[0178] Thus, these data confirm that these selected humanized antibodies are suitable for further clinical development.
[0179] Example 8. ADCC of humanized antibodies The ADCC reporter bioassay uses a surrogate readout at an earlier point in the ADCC MOA pathway activation: activation of gene transcription via the NFAT (nuclear factor of activated T cells) pathway in effector cells. In addition, the ADCC reporter bioassay uses engineered Jurkat cells as effector cells that stably express the FcγRIIIa receptor, the V158 (high affinity) mutant, and an NFAT response element that drives expression of firefly luciferase. Antibody bioactivity in the ADCC MOA is quantified via luciferase generated as a result of NFAT pathway activation; luciferase activity in effector cells is quantified by a luminescence readout. The signal is high and the assay background is low.
[0180] Serial dilutions of GPRC5D hu Ab were incubated with ADCC Bioassay target cells (expressing GPRC5D) and engineered Jurkat effector cells for induction for 6 hours at 37° C. Luciferase activity was quantified using Bio-Glo™ reagent.
[0181] The results are shown in FIG. 11 and demonstrate that these humanized antibodies induced strong ADCC activity against GPRC5D-overexpressing cell lines and endogenous MM (multiple myeloma) cell lines.
[0182] Example 9. Internalization of humanized antibodies This example tested humanized antibodies for their internationalization-inducing activity. This example used a new hydrophilic, bright pH sensor dye (pHAb dye), which is not fluorescent at neutral pH upon internalization but highly fluorescent at acidic pH, and can be used to detect the process of internalization. NCI-H929 cells and MM.1R cells, as target cells, endogenously expressed human GPRC5D. The detection antibody labeled with pHAb dye was added to evaluate the internalization of GPRC5D hu antibody in vitro.
[0183] Serial dilutions of GPRC5D hu antibodies were incubated for 24 hours at 37°C. Luciferase activity was detected. The results in Figure 12 show that these humanized antibodies have very strong internalization activity against both GPRC5D-overexpressing and endogenous MM cell lines.
[0184] Example 10. Killing activity of GPRC5D ADCs This example tested two antibody-drug conjugates (ADCs) for their target cell killing activity. These ADCs included 37B9C4 and 58F9G10, respectively, conjugated to the toxic drug monomethylauristatin E (MMAE).
[0185] Human GPRC5D expressing HEK293 and NCI-H929 engineered cells (HEK293 / H_GPRC5D and NCI-H929 / H_GPRC5D), GPRC5D endogenously expressing NCI-H929 and MM.1R cells were seeded in 96-well plates at 3000-4000 cells per well. The cells were treated with 37B9C4-MMAE and 58F9G10-MMAE at the respective concentrations for 5 days. Cell viability was measured by CellTite seeded in 96-well plates at 3000-4000 cells per well with r-Glo reagent. Luciferase activity was detected by Envison. The results show in Figure 13 and Table 12 that these humanized antibodies have very strong killing activity.
[0186] [Table 12]
[0187] Example 11. In vivo antitumor activity This example used a CDX animal model to test the anti-tumor activity of antibody 37B9C4 (H1L1).
[0188] In this study, 6-8 week-old female NCG mice (Jiangsu Jicui Yaokang Biotechnology Co., Ltd.) were used. Each mouse was inoculated subcutaneously in the right axilla (lateral side) with MM.1R tumor cells (2 × 106 cells) in 0.1 ml of PBS containing Matrigel (V:V = 1:1) for tumor growth. Animals were cultured until tumor volume reached approximately 60 mm 3 Randomization to groups was performed when the mean tumor volume in the vehicle group reached 2000 mm 37B9C4 was administered intravenously (iv) at doses of 1 mg / kg, 3 mg / kg, and 10 mg / kg on days 0, 7, and 14. 3 The experiment was terminated on the 19th day, when the tumor volume exceeded 100 mg / kg. The mean tumor volumes in the PBS group, 37B9C4 (1 mg / kg) group, 37B9C4 (3 mg / kg) group, and 37B9C4 (10 mg / kg) group were 2498.58 mm3, respectively. 3 , 1196.15mm 3 , 0.00mm 3 (6 / 6CR), and 0.00mm 3 The tumor size was measured bidimensionally using calipers three times a week, and the volume was calculated according to the formula: V = 0.5a × b 2 where "a" and "b" are the long and short diameters of the tumor, respectively, and are expressed in mm3. Data points represent group (n=6) means, and error bars represent standard error of the mean (SEM).
[0189] The body weight of MM.1R tumor-bearing mice was monitored periodically as an indirect measure of toxicity. Figure 14A shows the tumor growth curve of MM.1R tumor-bearing mice after administration of 37B9C4. The antibody dose-dependently inhibited tumor growth in this tumor model, and achieved complete tumor inhibition at 3 mg / kg or higher.
[0190] The detailed changes in body weight and the relative changes in body weight of MM.1R tumor-bearing mice after treatment are shown in Figure 14B. There was no significant weight loss in all groups of mice during the treatment period, demonstrating that the treatment was well tolerated by mice in the treatment groups and was safe.
[0191] The present disclosure is not limited in scope by the specific embodiments described, which are intended as an illustration of one of the individual aspects of the present disclosure, and any composition or method that is functionally equivalent is within the scope of the present disclosure. It will be apparent to those skilled in the art that various modifications and variations can be made to the methods and compositions of the present disclosure without departing from the spirit or scope of the present disclosure. Therefore, the present disclosure is intended to cover the modifications and variations of the present disclosure, provided that they fall within the scope of the appended claims and their equivalents.
[0192] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Claims
1. An antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to a cytotoxin, the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 42, a HCDR2 amino acid sequence of SEQ ID NO: 43, and a HCDR3 amino acid sequence of SEQ ID NO: 44; and 1. An ADC comprising: a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 45, a LCDR2 amino acid sequence of SEQ ID NO: 46, and a LCDR3 amino acid sequence of SEQ ID NO:
47.
2. 2. The ADC of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, 48, 49, or 50.
3. 3. The ADC of claim 1 or 2, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, 51, 52, or 53.
4. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, 48, 49, or 50; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, 51, 52, or 53; 4. The ADC of any one of claims 1 to 3.
5. 5. The ADC of any one of claims 1 to 4, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 48 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
51.
6. An antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to a cytotoxin, the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 29, a HCDR2 amino acid sequence of SEQ ID NO: 30, and a HCDR3 amino acid sequence of SEQ ID NO: 31; and 1. An ADC comprising: a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 32, a LCDR2 amino acid sequence of SEQ ID NO: 33, and a LCDR3 amino acid sequence of SEQ ID NO:
34.
7. 7. The ADC of claim 6, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, 35, 36, or 37.
8. 8. The ADC of claim 6 or 7, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, 38, 39, 40, or 41.
9. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, 35, 36, or 37; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, 38, 39, 40, or 41; 9. The ADC of any one of claims 6 to 8.
10. 10. The ADC of any one of claims 6 to 9, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 35 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
38.
11. An antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to a cytotoxin, the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 54, a HCDR2 amino acid sequence of SEQ ID NO: 55 or 60, and a HCDR3 amino acid sequence of SEQ ID NO: 56; and 1. An ADC comprising: a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO:57, a LCDR2 amino acid sequence of SEQ ID NO:58, and a LCDR3 amino acid sequence of SEQ ID NO:
59.
12. 12. The ADC of claim 11 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 15, 61, 62, 63, or 64.
13. 13. The ADC of claim 11 or 12, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 16, 65, 66, or 67.
14. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 15, 61, 62, 63, or 64; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 16, 65, 66, or 67; 14. The ADC of any one of claims 11 to 13.
15. 15. The ADC of any one of claims 11 to 14, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 61 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
65.
16. 15. The ADC of any one of claims 11 to 14, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:63 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
65.
17. An antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to a cytotoxin, the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 68, a HCDR2 amino acid sequence of SEQ ID NO: 69, and a HCDR3 amino acid sequence of SEQ ID NO: 70; and 1. An ADC comprising: a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 71, a LCDR2 amino acid sequence of SEQ ID NO: 72, and a LCDR3 amino acid sequence of SEQ ID NO:
73.
18. 18. The ADC of claim 17, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, 74, 75, 76, 77, 78 or 79.
19. 19. The ADC of claim 17 or 18, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2, 81, 82, 83, 84, 85, or 86.
20. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, 74, 75, 76, 77, 78, or 79; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2, 81, 82, 83, 84, 85, or 86; 20. The ADC of any one of claims 17 to 19.
21. 21. The ADC of any one of claims 17 to 20, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 76 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
82.
22. 21. The ADC of any one of claims 17 to 20, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 77 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
82.
23. 23. The ADC of any one of claims 1 to 22, wherein the cytotoxin is a maytansinoid or an auristatin.
24. 24. The ADC of claim 23, wherein the cytotoxin is selected from the group consisting of maytansine, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl), or N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1); monomethylauristatin-D (MMAD); monomethylauristatin E (MMAE); and monomethylauristatin F (MMAF).
25. 1. An antibody-drug conjugate (ADC) comprising an antibody, or antigen-binding fragment thereof, conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 42, a HCDR2 amino acid sequence of SEQ ID NO: 43, and a HCDR3 amino acid sequence of SEQ ID NO: 44; and 1. An ADC comprising: a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 45, a LCDR2 amino acid sequence of SEQ ID NO: 46, and a LCDR3 amino acid sequence of SEQ ID NO:
47.
26. 1. An antibody-drug conjugate (ADC) comprising an antibody, or antigen-binding fragment thereof, conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:48; and A light chain variable region comprising the amino acid sequence of SEQ ID NO:
51.
27. 1. An antibody-drug conjugate (ADC) comprising an antibody, or antigen-binding fragment thereof, conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 54, a HCDR2 amino acid sequence of SEQ ID NO: 55 or 60, and a HCDR3 amino acid sequence of SEQ ID NO: 56; and 1. An ADC comprising: a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO:57, a LCDR2 amino acid sequence of SEQ ID NO:58, and a LCDR3 amino acid sequence of SEQ ID NO:
59.
28. 1. An antibody-drug conjugate (ADC) comprising an antibody, or antigen-binding fragment thereof, conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:61; and A light chain variable region comprising the amino acid sequence of SEQ ID NO:
65.
29. 1. A pharmaceutical composition for treating hematological cancer comprising an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 42, a HCDR2 amino acid sequence of SEQ ID NO: 43, and a HCDR3 amino acid sequence of SEQ ID NO: 44; and A pharmaceutical composition comprising a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 45, a LCDR2 amino acid sequence of SEQ ID NO: 46, and a LCDR3 amino acid sequence of SEQ ID NO:
47.
30. 1. A pharmaceutical composition for treating hematological cancer comprising an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:48; and A pharmaceutical composition comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:
51.
31. 1. A pharmaceutical composition for treating hematological cancer comprising an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 54, a HCDR2 amino acid sequence of SEQ ID NO: 55 or 60, and a HCDR3 amino acid sequence of SEQ ID NO: 56; and A pharmaceutical composition comprising a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 57, a LCDR2 amino acid sequence of SEQ ID NO: 58, and a LCDR3 amino acid sequence of SEQ ID NO:
59.
32. 1. A pharmaceutical composition for treating hematological cancer comprising an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to monomethyl auristatin E (MMAE), the antibody or antigen-binding fragment thereof specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:61; and A pharmaceutical composition comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:
65.
33. 30. A pharmaceutical composition for treating hematological cancer comprising an ADC according to any one of claims 2 to 4, 6 to 10, 12 to 14, and 16 to 28.
34. 34. The pharmaceutical composition of any one of claims 29 to 33, wherein the hematological cancer is multiple myeloma.
35. An antibody or antigen-binding fragment thereof that specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein, a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 42, a HCDR2 amino acid sequence of SEQ ID NO: 43, and a HCDR3 amino acid sequence of SEQ ID NO: 44; and a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 45, a LCDR2 amino acid sequence of SEQ ID NO: 46, and a LCDR3 amino acid sequence of SEQ ID NO: 47; An antibody or an antigen-binding fragment thereof comprising:
36. The antibody or antigen-binding fragment thereof of claim 35, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, 48, 49, or 50.
37. The antibody or antigen-binding fragment thereof of claim 35 or 36, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, 51, 52, or 53.
38. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, 48, 49, or 50; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, 51, 52, or 53; 38. An antibody or antigen-binding fragment thereof according to any one of claims 35 to 37.
39. specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:48; and An antibody or antigen-binding fragment thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:
51.
40. specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 29, a HCDR2 amino acid sequence of SEQ ID NO: 30, and a HCDR3 amino acid sequence of SEQ ID NO: 31; and An antibody or antigen-binding fragment thereof comprising a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 32, a LCDR2 amino acid sequence of SEQ ID NO: 33, and a LCDR3 amino acid sequence of SEQ ID NO:
34.
41. The antibody or antigen-binding fragment thereof of claim 40, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, 35, 36, or 37.
42. 42. The antibody or antigen-binding fragment thereof of claim 40 or 41, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, 38, 39, 40, or 41.
43. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, 35, 36, or 37; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, 38, 39, 40, or 41; 43. An antibody or antigen-binding fragment thereof according to any one of claims 40 to 42.
44. 44. The antibody or antigen-binding fragment thereof of any one of claims 40 to 43, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 35 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
38.
45. specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 54, a HCDR2 amino acid sequence of SEQ ID NO: 55 or 60, and a HCDR3 amino acid sequence of SEQ ID NO: 56; and An antibody or antigen-binding fragment thereof comprising a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 57, a LCDR2 amino acid sequence of SEQ ID NO: 58, and a LCDR3 amino acid sequence of SEQ ID NO:
59.
46. The antibody or antigen-binding fragment thereof of claim 45, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 15, 61, 62, 63, or 64.
47. The antibody or antigen-binding fragment thereof of claim 45 or 46, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 16, 65, 66, or 67.
48. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 15, 61, 62, 63, or 64; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 16, 65, 66, or 67; 48. An antibody or antigen-binding fragment thereof according to any one of claims 45 to 47.
49. 49. The antibody or antigen-binding fragment thereof of any one of claims 45 to 48, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
65.
50. specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:61; and An antibody or antigen-binding fragment thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:
65.
51. specifically binds to human G protein-coupled receptor family C group 5 member D (GPRC5D) protein; a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 68, a HCDR2 amino acid sequence of SEQ ID NO: 69, and a HCDR3 amino acid sequence of SEQ ID NO: 70; and An antibody or antigen-binding fragment thereof comprising a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 amino acid sequence of SEQ ID NO: 71, a LCDR2 amino acid sequence of SEQ ID NO: 72, and a LCDR3 amino acid sequence of SEQ ID NO:
73.
52. 52. The antibody or antigen-binding fragment thereof of claim 51 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, 74, 75, 76, 77, 78, or 79.
53. 53. The antibody or antigen-binding fragment thereof of claim 51 or 52, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2, 81, 82, 83, 84, 85, or 86.
54. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, 74, 75, 76, 77, 78, or 79; the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2, 81, 82, 83, 84, 85, or 86; 54. An antibody or antigen-binding fragment thereof according to any one of claims 51 to 53.
55. 55. The antibody or antigen-binding fragment thereof of any one of claims 51 to 54, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 76 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
82.
56. 55. The antibody or antigen-binding fragment thereof of any one of claims 51 to 54, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:77 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
82.
57. 40. A pharmaceutical composition for treating hematological cancer comprising the antibody or antigen-binding fragment thereof of claim 39.
58. 51. A pharmaceutical composition for treating hematological cancer comprising the antibody or antigen-binding fragment thereof described in claim 50.
59. 57. A pharmaceutical composition for treating hematological cancer comprising an antibody or antigen-binding fragment thereof according to any one of claims 35 to 38, 40 to 49, and 51 to 56.
60. 60. The pharmaceutical composition of any one of claims 57 to 59, wherein the hematological cancer is multiple myeloma.
Citation Information
Patent Citations
anti-ror1 antibody
JP2018524284A
Anti-GPRC5D antibodies, bispecific antigen-binding molecules that bind GPRC5D and CD3, and uses thereof
JP2019527061A
Antibodies binding to GPRC5d
WO2019154890A1
